Publication details
Cerebrospinal fluid S100B levels reflect symptoms of depression in patients with non-inflammatory neurological disorders
| Authors | |
|---|---|
| Year of publication | 2012 |
| Type | Article in Periodical |
| Magazine / Source | Neuroscience Letters |
| MU Faculty or unit | |
| Citation | |
| Doi | http://dx.doi.org/10.1016/j.neulet.2012.09.003 |
| Field | Neurology, neurosurgery, neurosciences |
| Keywords | Depression; Anxiety; S100B protein; NSE; Cerebrospinal fluid |
| Description | Recent findings document numerous interactions between neuronal and glial systems that likely play a role in the pathophysiology of depression. These findings suggest that glia-derived neurotrophic protein S100B may play a significant role in developing depression. To test the relationship between S100B and depressive symptoms we designed cross-sectional clinical study including S100B serum and CSF levels in neurological patients with non-inflammatory disorders (NIND), who undergone cerebrospinal fluid assessment for diagnostic purposes. The present study was focused on psychometric testing of depression (BDI-II). anxiety (SAS) and alexithymia (TAS-20), and neurochemical measure of cerebrospinal fluid (CSF) and serum levels of S100B in 40 NIND inpatients [mean age 41.67]. The main result shows that S100B in CSF is significantly negatively correlated with BDI-II (Spearman R=-0.51, p < 0.0009) but not with SAS and TAS-20. The finding indicates that decreased level of Si COB in CSF is related to increased symptoms of depression in the NIND patients. (C) 2012 Elsevier Ireland Ltd. All rights reserved. |
| Related projects: |